MX384872B - Composición inyectable para reducción de grasa localizada, sin dolor, edema ni efectos secundarios, y método para preparar la misma. - Google Patents
Composición inyectable para reducción de grasa localizada, sin dolor, edema ni efectos secundarios, y método para preparar la misma.Info
- Publication number
- MX384872B MX384872B MX2019002289A MX2019002289A MX384872B MX 384872 B MX384872 B MX 384872B MX 2019002289 A MX2019002289 A MX 2019002289A MX 2019002289 A MX2019002289 A MX 2019002289A MX 384872 B MX384872 B MX 384872B
- Authority
- MX
- Mexico
- Prior art keywords
- pain
- side effects
- fat reduction
- edema
- composition
- Prior art date
Links
- 230000036407 pain Effects 0.000 title abstract 5
- 206010030113 Oedema Diseases 0.000 title abstract 4
- 230000000694 effects Effects 0.000 title abstract 4
- 239000007972 injectable composition Substances 0.000 title abstract 4
- 238000000034 method Methods 0.000 title abstract 3
- 230000000699 topical effect Effects 0.000 abstract 5
- 238000002347 injection Methods 0.000 abstract 4
- 239000007924 injection Substances 0.000 abstract 4
- 210000001789 adipocyte Anatomy 0.000 abstract 3
- 239000000203 mixture Substances 0.000 abstract 3
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 abstract 3
- 206010002091 Anaesthesia Diseases 0.000 abstract 2
- 206010006784 Burning sensation Diseases 0.000 abstract 2
- 206010015150 Erythema Diseases 0.000 abstract 2
- 206010054107 Nodule Diseases 0.000 abstract 2
- 208000003251 Pruritus Diseases 0.000 abstract 2
- 230000002159 abnormal effect Effects 0.000 abstract 2
- 230000037005 anaesthesia Effects 0.000 abstract 2
- 239000003814 drug Substances 0.000 abstract 2
- 229940079593 drug Drugs 0.000 abstract 2
- 231100000321 erythema Toxicity 0.000 abstract 2
- 210000002950 fibroblast Anatomy 0.000 abstract 2
- 230000007803 itching Effects 0.000 abstract 2
- 210000000663 muscle cell Anatomy 0.000 abstract 2
- 230000017074 necrotic cell death Effects 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 230000035807 sensation Effects 0.000 abstract 2
- 230000008961 swelling Effects 0.000 abstract 2
- 210000003556 vascular endothelial cell Anatomy 0.000 abstract 2
- 208000019901 Anxiety disease Diseases 0.000 abstract 1
- 108010007979 Glycocholic Acid Proteins 0.000 abstract 1
- RFDAIACWWDREDC-UHFFFAOYSA-N Na salt-Glycocholic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(=O)NCC(O)=O)C)C1(C)C(O)C2 RFDAIACWWDREDC-UHFFFAOYSA-N 0.000 abstract 1
- 208000028389 Nerve injury Diseases 0.000 abstract 1
- WBWWGRHZICKQGZ-UHFFFAOYSA-N Taurocholic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(=O)NCCS(O)(=O)=O)C)C1(C)C(O)C2 WBWWGRHZICKQGZ-UHFFFAOYSA-N 0.000 abstract 1
- 230000036506 anxiety Effects 0.000 abstract 1
- 230000006907 apoptotic process Effects 0.000 abstract 1
- 230000009089 cytolysis Effects 0.000 abstract 1
- RFDAIACWWDREDC-FRVQLJSFSA-N glycocholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 RFDAIACWWDREDC-FRVQLJSFSA-N 0.000 abstract 1
- 229940099347 glycocholic acid Drugs 0.000 abstract 1
- 230000001939 inductive effect Effects 0.000 abstract 1
- 230000004130 lipolysis Effects 0.000 abstract 1
- 230000008764 nerve damage Effects 0.000 abstract 1
- 231100000957 no side effect Toxicity 0.000 abstract 1
- 239000002904 solvent Substances 0.000 abstract 1
- WBWWGRHZICKQGZ-GIHLXUJPSA-N taurocholic acid Chemical compound C([C@@H]1C[C@H]2O)[C@@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@@H]([C@@H](CCC(=O)NCCS(O)(=O)=O)C)[C@@]2(C)[C@H](O)C1 WBWWGRHZICKQGZ-GIHLXUJPSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
- A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Dermatology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Child & Adolescent Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Plant Substances (AREA)
- Steroid Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
La presente invención se relaciona con una composición para reducir grasa localizada sin dolor, edema ni efectos secundarios, y con un método para preparar la misma. Más específicamente, la presente invención se relaciona con una composición que comprende ácido glicocólico (o una sal del mismo) o ácido taurocólico (o una sal del mismo) y fosfatidilcolina (PPC) en una proporción de mezcla particular para reducir grasa localizada sin efectos secundarios tales como dolor, edema, necrosis de células musculares, fibroblastos y células del endotelio vascular distintas de los adipocitos, anestesia de los sitios de administración, hinchamiento extenso, eritema, endurecimiento, parestesia, nódulo, prurito, sensación de ardor, daño nervioso, y disfagia, y con un método para preparar la misma. Se conoce que la preparación inyectable simple de DCA o preparación inyectable PPC en la cual se mezcla DCA como un agente solubilizante, que son las preparaciones inyectables convencionales para reducir grasa localizada, están acompañadas de dichos efectos secundarios tales como dolor, anestesia, hinchamiento extenso, edema localizado, eritema, endurecimiento, parestesia, nódulo, prurito, sensación de ardor, disfagia y lo similar debido a necrosis de células causada inevitablemente por la lisis de no sólo adipocitos sino también fibroblastos, células del endotelio vascular y células de músculo esquelético. De ese modo los pacientes se han estado quejando de dolor, malestar y ansiedad, con bajo cumplimiento. Por otra parte, la composición inyectable para reducir grasa localizada de acuerdo con la presente invención es una formulación segura y estable, realiza la lisis selectiva de adipocitos y tiene un excelente efecto en la inducción de apoptosis de adipocitos, de modo que es una excelente composición que mejora el cumplimiento y calidad de vida del paciente sin los efectos secundarios mencionados anteriormente.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20170051868 | 2017-04-21 | ||
| KR20170146264 | 2017-11-03 | ||
| PCT/KR2018/004642 WO2018194427A1 (ko) | 2017-04-21 | 2018-04-20 | 통증과 부종 그리고 부작용이 없는 국소지방 감소용 주사제 조성물 및 이의 제조방법 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2019002289A MX2019002289A (es) | 2019-09-26 |
| MX384872B true MX384872B (es) | 2025-03-14 |
Family
ID=63229610
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2019002289A MX384872B (es) | 2017-04-21 | 2018-04-20 | Composición inyectable para reducción de grasa localizada, sin dolor, edema ni efectos secundarios, y método para preparar la misma. |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US11298314B2 (es) |
| EP (1) | EP3479827B1 (es) |
| JP (1) | JP7034497B2 (es) |
| KR (1) | KR101887586B1 (es) |
| CN (1) | CN109862897B (es) |
| AU (1) | AU2018256263B2 (es) |
| CA (1) | CA3031678C (es) |
| CO (1) | CO2019004317A2 (es) |
| ES (1) | ES2949946T3 (es) |
| IL (1) | IL266873B2 (es) |
| MX (1) | MX384872B (es) |
| RU (1) | RU2736974C1 (es) |
| WO (1) | WO2018194427A1 (es) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX384872B (es) | 2017-04-21 | 2025-03-14 | Ami Pharm Co Ltd | Composición inyectable para reducción de grasa localizada, sin dolor, edema ni efectos secundarios, y método para preparar la misma. |
| KR102513115B1 (ko) | 2020-12-18 | 2023-03-22 | 주식회사 레시텍 | 리토콜릭산을 포함하는 국소지방 감소용 조성물 |
| KR20230080056A (ko) * | 2021-11-29 | 2023-06-07 | (주)아모레퍼시픽 | 릴린 및/또는 vegf-c의 생산 및/또는 활성 촉진제 및 이를 이용한 피부 외용제 |
| KR102669623B1 (ko) | 2024-01-04 | 2024-05-27 | 주식회사 아미팜 | 통증과 부종 그리고 부작용이 없는 국소지방 감소용 조성물 및 이의 투여방법 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6663885B1 (en) * | 1993-03-15 | 2003-12-16 | A. Natterman & Cie Gmbh | Aqueous liposome system and a method for the preparation of such a liposome system |
| DE10349979B4 (de) | 2003-10-24 | 2006-05-18 | Sanofi-Aventis Deutschland Gmbh | Medikamentöse gezielte lokale Lipolyse |
| US20050089555A1 (en) | 2003-10-24 | 2005-04-28 | Aventis Pharma Deutschland Gmbh | Medicinal targeted local lipolysis |
| EP1699432A2 (en) * | 2003-12-22 | 2006-09-13 | Aventis Pharmaceuticals, Inc. | Injectable phosphatidylcholine preparations |
| DE10361067A1 (de) | 2003-12-22 | 2005-07-14 | Aventis Pharma Deutschland Gmbh | Medikamentöse Lipolyse von Fettansammlungen |
| US20050143347A1 (en) * | 2003-12-22 | 2005-06-30 | Aventis Pharma Deutschland Gmbh | Medicinal lipolysis of accumulations of fat |
| ES2372499T3 (es) | 2004-05-19 | 2012-01-20 | Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center | Uso de un detergente para la eliminación no quirúrgica de grasa. |
| US7754230B2 (en) * | 2004-05-19 | 2010-07-13 | The Regents Of The University Of California | Methods and related compositions for reduction of fat |
| US20090221528A1 (en) * | 2004-06-28 | 2009-09-03 | Teresa Ann Denney | Therapeutic micro nutrient composition for lipolysis and sclerosis |
| RU2500686C2 (ru) | 2007-03-22 | 2013-12-10 | Дженентек, Инк. | АПОПТОТИЧЕСКИЕ АНТИТЕЛА ПРОТИВ IgE |
| CN101152189B (zh) * | 2007-10-12 | 2010-11-24 | 西藏海思科药业集团有限公司 | 多烯磷脂酰胆碱注射液及其制备方法 |
| US20140113883A1 (en) * | 2008-12-16 | 2014-04-24 | James Robert DeLuze | Therapeutic micro nutrient composition for lipolysis and sclerosis |
| KR101173652B1 (ko) | 2010-05-19 | 2012-08-13 | 박은희 | Ｐｐｃ 성분이 포함된 지방 분해 액상 조성물 제조 방법 |
| KR101545706B1 (ko) | 2013-05-10 | 2015-08-26 | 주식회사 아미팜 | 포스파티딜콜린을 포함하는 지방 분해용 조성물 및 이의 제조방법 |
| US10729700B2 (en) * | 2014-06-27 | 2020-08-04 | Medytox Inc. | Methods and compositions of bile acids and salts for reduction of fat |
| MX384872B (es) | 2017-04-21 | 2025-03-14 | Ami Pharm Co Ltd | Composición inyectable para reducción de grasa localizada, sin dolor, edema ni efectos secundarios, y método para preparar la misma. |
-
2018
- 2018-04-20 MX MX2019002289A patent/MX384872B/es unknown
- 2018-04-20 RU RU2019112583A patent/RU2736974C1/ru active
- 2018-04-20 EP EP18787918.4A patent/EP3479827B1/en active Active
- 2018-04-20 ES ES18787918T patent/ES2949946T3/es active Active
- 2018-04-20 KR KR1020180046228A patent/KR101887586B1/ko active Active
- 2018-04-20 CA CA3031678A patent/CA3031678C/en active Active
- 2018-04-20 WO PCT/KR2018/004642 patent/WO2018194427A1/ko not_active Ceased
- 2018-04-20 IL IL266873A patent/IL266873B2/en unknown
- 2018-04-20 JP JP2019547440A patent/JP7034497B2/ja active Active
- 2018-04-20 US US16/311,960 patent/US11298314B2/en active Active
- 2018-04-20 AU AU2018256263A patent/AU2018256263B2/en active Active
- 2018-04-20 CN CN201880002788.6A patent/CN109862897B/zh active Active
-
2019
- 2019-04-29 CO CONC2019/0004317A patent/CO2019004317A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IL266873B2 (en) | 2024-04-01 |
| CN109862897A (zh) | 2019-06-07 |
| RU2736974C1 (ru) | 2020-11-23 |
| EP3479827A4 (en) | 2019-08-07 |
| CA3031678A1 (en) | 2018-10-25 |
| IL266873A (en) | 2019-08-29 |
| WO2018194427A1 (ko) | 2018-10-25 |
| EP3479827A1 (en) | 2019-05-08 |
| CO2019004317A2 (es) | 2019-05-10 |
| IL266873B1 (en) | 2023-12-01 |
| WO2018194427A8 (ko) | 2019-01-03 |
| CN109862897B (zh) | 2024-01-30 |
| CA3031678C (en) | 2021-08-31 |
| AU2018256263B2 (en) | 2021-05-06 |
| EP3479827B1 (en) | 2023-05-10 |
| AU2018256263A1 (en) | 2019-05-16 |
| KR101887586B1 (ko) | 2018-08-10 |
| BR112019008065A2 (pt) | 2019-07-02 |
| JP2020517581A (ja) | 2020-06-18 |
| US20190201328A1 (en) | 2019-07-04 |
| JP7034497B2 (ja) | 2022-03-14 |
| US11298314B2 (en) | 2022-04-12 |
| ES2949946T3 (es) | 2023-10-04 |
| MX2019002289A (es) | 2019-09-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX384872B (es) | Composición inyectable para reducción de grasa localizada, sin dolor, edema ni efectos secundarios, y método para preparar la misma. | |
| BRPI0510074A (pt) | composições farmacêuticas para o tratamento de distúrbios sexuais ii | |
| MX2017001372A (es) | Sales de berberina, sales ursodesoxicolicas y combinaciones, metodos de preparacion y aplicacion de las mismas. | |
| BR112017017888A2 (pt) | derivados fluorados do ácido tetraidronaftiridinil nonanoico derivados e usos destes | |
| BR112022009805A2 (pt) | Derivados de piridopirimidinona como antagonistas de ahr | |
| CO2022018636A2 (es) | Moduladores de il-17a | |
| CO2019007409A2 (es) | Derivados de la pirimidin enona tricíclica para la inhibición de rorγ y otros usos | |
| BR112015030723A2 (pt) | compostos de tetra-hidrocarbazol e carbazol carboxamida substituídos úteis como inibidores da quinase | |
| EA201892367A1 (ru) | Введение биспецифической конструкции, связывающейся с cd33 и cd3, для применения в способе лечения миелоидного лейкоза | |
| BR112014011641A2 (pt) | composto; composição; uso de um composto; método para tratar pelo menos uma doença, distúrbio ou condição selecionada de obesidade, sobrepeso ou distribuição de gordura anormal e condições ou doenças associadas com os mesmos em um sujeito em necessidade do mesmo; método para remodelar tecido adiposo branco para tecido adiposo tipo marrom em um sujeito; método para tratar uma doença, distúrbio ou condição associada com ou se beneficiando da remodelação de tecido adiposo branco para tecido adiposo tipo marrom em um sujeito; e método para reduzir o tecido adiposo branco (wat) em um sujeito em necessidade do mesmo | |
| JOP20220107A1 (ar) | مثبطات egfr تفارغية وطرق استخدامها | |
| SA522432999B1 (ar) | C-17 مركبات تراي تريبينويد تخليقية ذات مجموعات استبدال اساسها نيتروجين عند وطرق استخدامها | |
| EA201291335A1 (ru) | Фармацевтические композиции для местного применения | |
| Landy | Combined use of clozapine and electroconvulsive therapy | |
| Hu et al. | A crucial role of HMGB1 in orofacial and widespread pain sensitization following partial infraorbital nerve transection | |
| BR112014030777A2 (pt) | método e composição para aliviar sintomas de tumor | |
| EA202192017A1 (ru) | Липофильные местные фармацевтические композиции апремиласта | |
| Jiang et al. | Safety and efficacy of HQP1351, a 3rd generation oral BCR-ABL inhibitor in patients with tyrosine kinase inhibitor—resistant chronic myelogenous leukemia: preliminary results of phase I study | |
| Comassetto et al. | Continuous infusion of propofol at variable rates in a time dependent in cats. | |
| Yoshimura et al. | ESRA19-0146 Efficacy of ultrasound-guided radiofrequency ablation for genicular nerve in patients with chronic knee pain after total knee arthroplasty | |
| Cosentino et al. | Priapism secondary to tamsulosin: a case report | |
| Zaky et al. | ESRA19-0686 ‘Don’t GA (S) me now!’: Using a combined paravertebral and pecto-intercostal fascial plane block for awake breast surgery to reduce post-operative morbidity | |
| RU2012130936A (ru) | Лечение остеопороза | |
| Oh | Transient Receptor Potential (TRP) Channels as a Mediator of Tooth Pain | |
| Nakajima | ESRA19-0141 A case of ultrasound-guided erector spinae plane block using phenol for abdominal spasticity in a patient with spinal cord injury |